Novel small-molecule inhibitors of the SARS-CoV-2 spike protein binding to neuropilin 1Kolarič, Anja (Avtor) Jukič, Marko (Avtor) Bren, Urban (Avtor) neuropilin 1SARS-CoV-2COVID-19spike binding inhibitorsvirtual screeningsmall-molecule antagonistsmolecular dockingin vitro binding assayFurin cleavage of the SARS-CoV-2 spike protein results in a polybasic terminal sequence termed the C-end rule (CendR), which is responsible for the binding to neuropilin 1 (NRP1), enhancing viral infectivity and entry into the cell. Here we report the identification of 20 small-molecule inhibitors that emerged from a virtual screening of nearly 950,000 drug-like compounds that bind with high probability to the CendR-binding pocket of NRP1. In a spike NRP1 binding assay, two of these compounds displayed a stronger inhibition of spike protein binding to NRP1 than the known NRP1 antagonist EG00229, for which the inhibition of the CendR peptide binding to NRP1 was also experimentally confirmed. These compounds present a good starting point for the design of small-molecule antagonists against the SARS-CoV-2 viral entry.MDPI, Molecular Diversity Preservation International20222025-05-09 13:26:06Članek v reviji92745UDK: 577COBISS_ID: 95574275DOI: 10.3390/ph15020165ISSN pri članku: 1424-8247sl© 2022 by the authors